According to Moderna
's latest financial reports the company has $8.60 B in cash and cash equivalents.
A companyโs cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.
Year | Cash on Hand | Change |
---|---|---|
2023-12-31 | $8.60 B | -13.11% |
2022-12-31 | $9.90 B | -7.69% |
2021-12-31 | $10.72 B | 132.79% |
2020-12-31 | $4.60 B | 317.77% |
2019-12-31 | $1.10 B | -27.5% |
2018-12-31 | $1.52 B | 101.24% |
2017-12-31 | $0.75 B | -28.55% |
2016-12-31 | $1.05 B |
Company | Cash on Hand | differencediff. | Country |
---|---|---|---|
Johnson & Johnson JNJ | $22.92 B | 166.47% | ๐บ๐ธ USA |
Novartis NVS | $13.96 B | 62.27% | ๐จ๐ญ Switzerland |
Merck MRK | $7.09 B | -17.56% | ๐บ๐ธ USA |
Regulus Therapeutics RGLS | $30.78 M | -99.64% | ๐บ๐ธ USA |
Dicerna Pharmaceuticals DRNA | N/A | N/A | ๐บ๐ธ USA |
Athersys ATHX | $1.02 M | -99.99% | ๐บ๐ธ USA |
Alnylam Pharmaceuticals
ALNY | $2.43 B | -71.65% | ๐บ๐ธ USA |
Arrowhead Pharmaceuticals
ARWR | $0.22 B | -97.44% | ๐บ๐ธ USA |